Finance

Funding Statement

EFNA funding arises from a small number of sources, including the pharmaceutical and medical device industries, the European Commission and others. Some of the grants are specific for particular EFNA projects and, where possible, we try to involve a consortium of donors for each project.

No donor, including the European Commission, has had any undue influence of any kind over EFNA’s activities, nor are there any conflicts of interest.

It is important to remember that EFNA is an extremely broadly-based organisation, which attempts to improve the quality of life for people in Europe living with neurological illness. Our projects are equally broad and tend to deal with issues generic to all or several neurological conditions and education rather than with specific drugs or other treatments. EFNA’s relationships within the pharmaceutical and medical device industry are usually at the level of government affairs and policy and our relationships with all sponsors/funders are regulated carefully by our “Code of Practice”.

Grants

Grants are listed by donor, with the percentage of total EFNA funding shown. These should be considered alongside funding in other years, as the figures below merely show the ‘snapshot’ of funds received as at 31 December in the year concerned.

The total amount of EFNA funding for each year may be found in the audited accounts, on this website but these accounts do not include, of course, any ‘donations in kind’ such as staff secondment. In the tables of percentages “EFNS” is the acronym for European Federation of Neurological Societies.

2006
Source % of Total funding
Novartis (Restricted) 2.62
Movers and Shakers (UK Charity) 15.40
GSK (Restricted) 1.93
GE Healthcare (Restricted) 15.03
GSK (Unrestricted) 14.48
Alexion Pharma 20.21
GSK (Restricted) 15.56
European Parkinson's Disease 0.39
Eli Lilly (Resticted) 2.05
EFNS (Staff secondment) 12.07
Other 0.26
2005
Source % of Total funding
Britannia Pharma 1.36
Valeant 1.37
GSK 2.72
European Commission 83.49
Schering 3.80
Merck Sharpe & Dohme 2.76
Serono 0.38
EFNS (Staff secondment) 3.92
Other 0.21
2004
Unrestricted grants % of total funding
GlaxoSmithKline 9.9
Novartis 29.6
Merck Sharp & Dohme  9.9
   
Restricted Grant (EFNA Project)  
Novartis 24.3
   
Seconded Staff  
European Federation of Neurological Societies 22.4
   
Other small items of income  
Including bank interest 3.9